A plethora of work has reported that IDH mutations promote metabolic adaptations [81–83], altered cellular differentiation [84, 85] and metabolic reprogramming of the immune cells infiltrating the tumour [86, 87]. This evidence concerns the gene IDH2 and neoplasm.